What do kids think of their parents' RA? Amgen's new Enbrel push offers a few ideas

Print 10 August 2017
Beth Snyder Bulik / FiercePharmaMarketing

In Amgen’s latest campaign for Enbrel, kids are speaking up. Two new TV commercials feature children talking about their parents’ painful arthritis and their worries about it. The “Being There” campaign includes one TV ad focused on a mother, and another on a father. The TV ads began running last week, backed by combined spending of just under $2 million so far, according to data from real-time TV tracker iSpot.tv.

The Mom ad specifies rheumatoid arthritis, while the Dad TV commercial focuses on psoriatic arthritis and also stars a familiar face. Longtime spokesman pro golfer Phil Mickelson is featured, along with his “daughter,” who talks about her fears about what his joint pain means. Both children are played by actors, an Amgen spokeswoman said.

The “multichannel campaign was developed based on insights we’ve learned from patients, including the fact that they are motivated to learn more about their disease when they consider how it impacts their lives,” the spokeswoman said via email.

The new ads also introduce Enbrel’s online Joint Damage Simulator, which people can use to gauge the progression of their arthritis. The simulator visually shows how joint damage from either rheumatoid or psoriatic arthritis can increase over time. It includes a discussion guide that patients can print and share with their doctor.

Enbrel was first approved by the FDA 14 years ago, but it remains a blockbuster for Amgen. Last year sales totaled $5.97 billion, up 11% over 2015 sales. Amgen did note in its 2016 year-end report, however, that “the increases in Enbrel sales in 2016 and 2015 were driven primarily by an increase in net selling price, offset partially by the impact of competition. In 2017, we expect intensifying competition and relatively little benefit from net selling price changes.”

Competitors looking to introduce biosimilars include Novartis’ Sandoz, which won FDA approval for Erelzi as a replacement for Enbrel in 2016. However, Novartis is in a protracted lawsuit with Amgen, which sued the Swiss drugmaker over patent issues even before Erelzi was approved, accusing Novartis of “piggybacking on” its breakthrough efforts. Erelzi likely won’t come on market until 2018 at the earliest.

Source

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news